Emmaus Life Sciences Receives Scientific Advice From the EMA Regarding Xyndari™

TORRANCE Calif., July 29, 2020 (GLOBE NEWSWIRE) — Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that the European Medicines Agency (EMA) issued scientific advice to Emmaus regarding the clinical development pathway for Xyndari™ for the treatment of sickle cell disease. Xyndari™ is the European brand name for the same Emmaus prescription product, Endari®, approved by the FDA and Israeli Ministry of Health.